Can Combination Therapy Improve Outcomes in Geriatric Dogs with Congestive Heart Failure?

Congestive heart failure (CHF) remains one of the most challenging cardiac conditions encountered in geriatric canine practice. As dogs age, the prevalence of acquired cardiac disorders such as myxomatous mitral valve disease (MVD) and dilated cardiomyopathy (DCM) rises substantially¹, often progressing to CHF with significant morbidity and reduced survival. 

The study by Dhiman et al. evaluated different therapeutic protocols in geriatric dogs with CHF and provided clinically relevant insights into how combination therapy may improve patient outcomes. Rather than focusing solely on symptomatic relief, the study explored how different drug combinations influenced survival, cardiac biomarkers, electrocardiographic findings, and overall clinical recovery². 

Evaluating Three Therapeutic Approaches² 

Twenty-four geriatric dogs diagnosed with CHF were divided into three treatment groups. 

• Group I received digoxin-based therapy  

• Group II received pimobendan-based therapy  

• Group III received a combination of pimobendan and carvedilol  

All dogs additionally received conventional CHF management including furosemide, spironolactone, and ACE inhibitors such as enalapril or benazepril. 

Notably, the carvedilol-based protocol was selectively used in dogs presenting with severe tachycardia, atrial fibrillation, and marked hypertension, making this group particularly relevant from a clinical standpoint. 

Combination Therapy Produced Better Clinical Resolution² 

One of the most important observations from the study was the degree of symptomatic improvement seen in dogs treated with carvedilol and pimobendan together. 

The investigators assessed multiple clinical indicators including: 

• Dyspnoea  

• Ascites  

• Syncope  

• Exercise intolerance  

• Nocturnal coughing  

• Pathological arrhythmias  

Group III demonstrated the lowest mean clinical score by day 42, indicating superior resolution of CHF-associated signs compared to the other treatment protocols. 

Dogs receiving combination therapy also showed better improvement in exercise tolerance and respiratory distress, both of which are critical indicators of quality of life in CHF patients. 

ECG Changes Reflected Therapeutic Success² 

The study provided several clinically valuable electrocardiographic observations. 

Pre-treatment ECG abnormalities included: 

• Atrial fibrillation  

• Sinus bradycardia  

• Electrical alternans  

• Atrial premature complexes  

• Low QRS amplitudes  

• ST segment elevation  

Following treatment, many dogs demonstrated normalization or marked improvement in rhythm disturbances and conduction abnormalities. 

For example, dogs with atrial fibrillation and severe DCM showed improved ECG patterns after Group III therapy, while cases with low QRS complexes improved following thoracocentesis and stabilization. 

These findings emphasize the importance of serial ECG monitoring not only for diagnosis but also for evaluating therapeutic response in canine CHF cases. 

Cardiac Troponin-I Helped Assess Myocardial Recovery² 

Cardiac troponin-I (cTn-I) was significantly elevated in all CHF groups at baseline, indicating active myocardial injury. 

However, treatment response varied substantially among protocols. 

The most pronounced reduction in cTn-I levels was observed in Group III, followed by Group II. Dogs treated with digoxin alone showed comparatively smaller reductions. 

According to Dhiman et al., carvedilol likely contributed through reduction of sympathetic cardiac stress and its antioxidant effects, while pimobendan improved myocardial performance through positive inotropic and vasodilatory actions. 

From a practical perspective, the findings support the growing value of cardiac biomarkers in monitoring treatment response and disease progression in canine cardiology. 

Survival Outcomes Favoured Multidrug Therapy 

Survival analysis revealed notable differences among treatment groups². 

• Group I recorded a survival rate of 33.34%  

• Group II showed a survival rate of 44.45%  

• Group III achieved the highest survival rate at 66.67%  

Despite including dogs with more severe cardiac presentations, the carvedilol-pimobendan combination group demonstrated the best overall outcomes. 

The authors suggested that carvedilol may help reduce adverse ventricular remodelling and excessive sympathetic stimulation, both of which contribute to CHF progression. 

Clinical Relevance for Veterinary Practice 

The study highlights the growing role of multidrug therapy in advanced canine CHF management. While pimobendan remains an important component of CHF treatment, the addition of carvedilol appeared to provide additional benefits in rhythm stabilization, clinical recovery, myocardial protection, and survival. 

For veterinarians managing geriatric cardiac patients, the findings reinforce the importance of individualized treatment planning based on disease severity, arrhythmia burden, and haemodynamic status rather than relying on conventional therapy alone. 

References 

1. Koduru R, Rao VV, Rani LN, Kumar PR, Sreenu M. Role of biomarkers in the diagnosis of myxomatous mitral valve disease in canines. Int J Vet Sci Anim Husb. 2025;10(9):334-337. https://www.doi.org/10.22271/veterinary.2025.v10.i9e.2576 

2. Dhiman A, Sharma P, Bodh D, Katoch A, Sharma A, Kumar A. Evaluating treatment protocols for congestive heart failure in geriatric dogs. INTERNATIONAL JOURNAL. 2025;9(1S):281-90. https://doi.org/10.33545/26174693.2025.v9.i1Sd.3481